Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent...

Area of Science:

• Vascular Biology
• Cell Signaling
• Molecular Medicine

Background:

• Lymphatic vessels are crucial for maintaining fluid homeostasis and immune surveillance.
• Dysfunctional lymphatic vessels are implicated in various diseases, including lymphedema and cancer metastasis.
• Understanding the regulation of lymphangiogenesis is vital for developing targeted therapies.

Purpose of the Study:

• To investigate the role of Glycogen Synthase Kinase 3 beta (GSK3-β) in regulating lung lymphatic endothelial cell lymphangiogenesis.
• To elucidate the molecular mechanisms underlying GSK3-β-mediated effects on lymphatic vessel formation.
• To explore the interplay between GSK3-β, the mTOR pathway, and beta-catenin in lymphangiogenesis.

Main Methods:

• In vitro studies using lung lymphatic endothelial cells.
• Pharmacological inhibition and genetic silencing of GSK3-β.
• Analysis of the mammalian/mechanistic target of rapamycin (mTOR) pathway components (PTEN, AKT, p-P70S6kinase).
• Assessment of beta-catenin levels and function.

Main Results:

• GSK3-β inhibition significantly increased lymphangiogenesis in lung lymphatic endothelial cells.
• Inhibition of GSK3-β led to PTEN activation, decreased AKT activation, and reduced mTOR pathway signaling.
• GSK3-β inhibition resulted in increased beta-catenin levels.
• Beta-catenin was essential for GSK3-β-induced lymphangiogenesis.

Conclusions:

• GSK3-β acts as a negative regulator of lymphangiogenesis in lung lymphatic endothelial cells.
• GSK3-β inhibition promotes lymphangiogenesis via activation of beta-catenin and suppression of the mTOR pathway.
• Targeting GSK3-β and modulating beta-catenin signaling may represent a therapeutic strategy for lymphatic disorders.